Eight-cycle rituximab therapy resulted in complete remission in primary cutaneous marginal zone lymphoma

Leuk Res. 2010 Jul;34(7):e160-3. doi: 10.1016/j.leukres.2010.02.013. Epub 2010 Mar 12.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Drug Administration Schedule
  • Hepatitis B, Chronic / complications
  • Hepatitis B, Chronic / drug therapy
  • Humans
  • Immunophenotyping
  • Lamivudine / therapeutic use
  • Lymphoma, B-Cell, Marginal Zone / complications
  • Lymphoma, B-Cell, Marginal Zone / diagnosis
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Male
  • Remission Induction
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Rituximab
  • Skin Neoplasms / complications
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Antiviral Agents
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Rituximab